{"id":"ibandronate-capecitabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Osteonecrosis of the jaw"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ibandronate is a bisphosphonate that reduces osteoclast-mediated bone resorption, potentially decreasing skeletal complications and bone metastases. Capecitabine is a fluoropyrimidine carbamate prodrug that is converted to 5-fluorouracil, inhibiting thymidylate synthase and disrupting DNA synthesis in cancer cells. The combination targets both bone metastatic disease and systemic tumor burden.","oneSentence":"This combination uses ibandronate to inhibit bone resorption and capecitabine to inhibit thymidylate synthase for antitumor activity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:48:10.007Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer with bone involvement"}]},"trialDetails":[{"nctId":"NCT00196859","phase":"PHASE3","title":"Study in Elderly Patients With Early Breast Cancer (ICE)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2004-06","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT00196872","phase":"PHASE3","title":"A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2004-07","conditions":"Breast Cancer","enrollment":3000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ibandronate, Capecitabine","genericName":"Ibandronate, Capecitabine","companyName":"GBG Forschungs GmbH","companyId":"gbg-forschungs-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses ibandronate to inhibit bone resorption and capecitabine to inhibit thymidylate synthase for antitumor activity. Used for Metastatic breast cancer with bone involvement.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}